Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
暂无分享，去创建一个
Jeffrey W. Clark | A. Iafrate | A. Shaw | S. Ou | R. Salgia | G. Shapiro | D. Costa | P. Stephenson | K. Wilner | B. Solomon | R. Maki | D. Camidge | E. Kwak | J. Clark | Yiyun Tang | K. Ruffner | S. Ou | P. Lorusso | Y. Tang | Y. Bang | P. LoRusso